20/20 Biolabs, Inc.

AIDX

Explore Our Financial Data > Companies > 20/20 Biolabs, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AIDX
CIK	0001139685
SIC	8734
Sector	Services
Industry Category	Business Services
Industry Group	Services – Research, Development, Testing Labs

Contact

Address	9430 KEY WEST AVENUE, SUITE 100, ROCKVILLE, MD, 20850
Website	2020biolabs.com
Phone	2404536339
CEO	Jonathan Cohen
Employees	14

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$2.04 million
Pre-Tax Income	$-5.82 million
Net Income	$-5.81 million
Net Income to Common	$-7.01 million
EPS	$-0.97

View All

Balance Sheet

Cash	$4.55 million
Assets	$6.12 million
Liabilities	$2.96 million
Common Equity	$1.62 million
Liabilities & Equity	$6.12 million

View All

Cash Flow Statement

Net Income	$-5.81 million
Cash From Operating Activities	$-2.79 million
Cash From Investing Activities	$-12,854.00
Cash From Financing Activities	$6.33 million
Change in Cash	$3.52 million

View All

Calculations

NOPAT	$-3.08 million
EBITDA	$-3.85 million
Price to Earnings	N/A
Price to Book	$1.42
ROE	-184.04%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy

CEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives Webinar to Be Held Wednesday, November 4, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of can

Article Link

20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026

Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Sum

Article Link

20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model

President and CEO Jonathan Cohen to Discuss Implications for Multi-Cancer Early Detection, Preliminary Interest from Laboratories Across the United States, and New State Funding for Firefighter Cancer Screening Webinar to Be Held Wednesday, October 7, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tes

Article Link

Profound Medical Stock And 2 Canadian AI Healthcare Stocks To Watch

Canada’s Ivey PMI recently hit a multi year high, hinting that businesses are spending again on tools that cut costs and raise productivity. That backdrop puts artificial intelligence in healthcare on many watchlists. AI can help Canadian hospitals and drug developers do more with limited budgets. This article walks through three AI focused healthcare stocks from our screener that could interest investors watching this shift. The stocks below are just a sample from this theme, and the full...

Article Link

Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results

Price targets for Healwell AI have been adjusted within a CA$1.50 to CA$2.00 range, with some analysts moving up to CA$2.00 and others trimming down to CA$1.50. This split reflects different views on how recent quarterly execution lines up with what investors should be willing to pay for the stock today. As you read on, you will see how to interpret these shifting targets and track the evolving narrative around Healwell AI for your own decision making. Analyst Price Targets don't always...

Article Link